Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;14(1):247-265.
doi: 10.1007/s13346-023-01397-6. Epub 2023 Aug 1.

Nano-drug delivery system targeting FAP for the combined treatment of oral leukoplakia

Ran Li  1   2 , Yingjiao Zhao  3   4 , Tiantian Liu  3   4 , Yanwei Li  3   4 , Chaoqiong Wan  3   4 , Ruifang Gao  3   4 , Chen Liu  3   4 , Xianqi Li  3   5 , Bing Li  3
Affiliations

Nano-drug delivery system targeting FAP for the combined treatment of oral leukoplakia

Ran Li et al. Drug Deliv Transl Res. 2024 Jan.

Abstract

Oral leukoplakia (OLK) has received much attention due to its potential risk of malignant transformation. Studies have shown that when drug therapy is combined with photothermal therapy (PTT), not only can the cytotoxicity of the drug be enhanced, but also the heat energy can be used to kill the lesion cells, so we can combine drug therapy with PTT to enhance the therapeutic effect on OLK. However, with certain drawbacks due to its lack of targeting, fibroblast activating protein (FAP) has become an attractive target for OLK combination therapy. In this study, we used NGO-PEG loaded with FAP-targeting peptide (F-TP) and celecoxib (CXB) to construct a nano-drug delivery system CGPF for targeting OLK with high FAP expression and confirmed the biocompatibility and therapeutic efficacy of CGPF by in vitro and in vivo experiments. Overall, the novel nano-drug delivery system CGPF proposed in this study showed a very significant potential for the combination therapy of OLK.

Keywords: Drug therapy; Nanomedicine; Oral leukoplakia; Photodynamic therapy; Targeted therapy.

PubMed Disclaimer

References

    1. van der Waal I. Historical perspective and nomenclature of potentially malignant or potentially premalignant oral epithelial lesions with emphasis on leukoplakia-some suggestions for modifications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):577–81. - PubMed - DOI
    1. Ding T, Zou J, Qi J, et al. Mucoadhesive nucleoside-based hydrogel delays oral leukoplakia canceration. J Dent Res. 2022;101(8):921–30. - PubMed - DOI
    1. Holmstrup P, Vedtofte P, Reibel J, et al. Oral premalignant lesions: is a biopsy reliable? Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2007;36(5):262–6. - DOI
    1. Kerr AR, Lodi G. Management of oral potentially malignant disorders. Oral Dis. 2021;27(8):2008–25. - PubMed - DOI
    1. Annaji M, Poudel I, Boddu SHS, et al. Resveratrol-loaded nanomedicines for cancer applications. Cancer reports (Hoboken, NJ). 2021;4(3): e1353. - DOI

LinkOut - more resources